Results 91 to 100 of about 5,756 (231)
Abciximab in the treatment of coronary artery disease [PDF]
, 2013 Antiplatelet therapy constitutes a cornerstone in the strategies aimed at the effective management of acute coronary syndrome. Abciximab is the oldest and most commonly used intravenous antiplatelet agent in this context, in particular when an invasive ...
Jayasinghe, Rohan +2 more
core +4 more sources
Off-target effects of glycoprotein IIb/IIIa receptor inhibitors [PDF]
, 2014 Soon after identification of the platelet membrane glycoprotein (GP) IIb/IIIa, it has become a target of antiplatelet therapy. There are 3 intravenous GP IIb/IIIa receptor inhibitors, namely— eptifibatide, tirofiban and abciximab, used in the ...
Adamski, Piotr +7 more
core +2 more sources
Evidence-Based Complementary and Alternative Medicine, Volume 2024, Issue 1, 2024.Cardiovascular diseases (CVDs) have been the major cause of mortality all around the globe. Lespedeza cuneata abbreviated as L. cuneata with the authority name of Dumont de Courset (G. Don) is a perennial flowering plant commonly grown in Asian countries such as Korea, Japan, China, and Taiwan. We aimed to investigate the L.
Abdul Wahab Akram +3 more
wiley +1 more source
Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study [PDF]
, 2001 BACKGROUND: Limited information has been published regarding how specific processes for event adjudication can affect event rates in trials. We reviewed nonfatal myocardial infarctions (MIs) reported by site investigators in the international Platelet ...
Akkerhuis, Martijn +16 more
core +4 more sources
Bridging Experience With Eptifibatide After Stent Implantation
Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine, 2016 Background: Patients who have undergone intracoronary stent implantation often require surgery within the first year after the procedure. Planned or emergent surgical intervention requires interruption of antiplatelet therapy and is associated with an increased risk of stent thrombosis. Eptifibatide, an intravenous glycoprotein
Marie Gerhard-Herman +3 more
openaire +2 more sources
Folia Histochemica et Cytobiologica, 2010 Abciximab (Abci) and eptifibatide (Epti) are antiaggregate drugs which may reduce thrombotic complications inacute coronary syndromes. The aim of this work was the investigation of the interaction between the phospholipid-GPIIb/IIIa glycoprotein complex ...
Ewa Gorodkiewicz +2 more
doaj
Abciximab‐Associated Thrombocytopenia After Previous Tirofiban‐Related Thrombocytopenia [PDF]
, 2006 Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90080/1/phco.26.3.423 ...
Dorsch, Michael P. +3 more
core +1 more source
Кардиоваскулярная терапия и профилактика, 2008 The review presents literature data on the key role of platelet aggregation (PA) for intracoronary thrombogenesis in various acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI).
T. A. Batyraliev +4 more
doaj
A comprehensive evaluation of the activity and selectivity profile of ligands for RGD-binding integrins [PDF]
, 2017 Integrins, a diverse class of heterodimeric cell surface receptors, are key regulators of cell structure and behaviour, affecting cell morphology, proliferation, survival and differentiation.
Cavalcanti-Adam, Elisabetta Ada +12 more
core +2 more sources
Cost-Effectiveness of Platelet Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Non–ST-Elevation Acute Coronary Syndromes [PDF]
, 2000 Daniel B. Mark +9 more
openalex +1 more source